• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Interview with Gloria Oliver Rodriguez

2016-04-27News

What is your current role in EPAD?

I am a member of the Legal & IP (intellectual property) Committee (LIPC), representing Barcelonaβeta Brain Research Centre (BBRC) that is co-leading the project and provides the Iberian Lead and a Trial Delivery Centre. The LIPC is composed of six members who are experts in legal, business, or intellectual property matters. We participate in regular discussions by conference calls, and at least once a year we meet face-to-face preferably during the General Assembly Meeting. Our mission is to assist the Steering Committee and the General Assembly in ensuring the correct application of IP ownership and access right clauses in relation to the Associated Trial Delivery Centres, Associated Scientific Collaborators, and Accession of new Participants to the Agreement, and other potential areas where legal or intellectual property advice is useful.

What did you do prior to joining EPAD?

I am part of the BBRC team from its very beginning, assuming the Managing Director Role. I am responsible for directing and controlling the institution’s operations as well as giving strategic guidance and direction to the General Director and the Board to ensure that the BBRC achieves its mission and objectives. To highlight some of my annual functions I would mention that I am responsible of preparing, gaining acceptance, and monitoring the implementation of the yearly budget to ensure its targets are met. In addition, I also lead the processes to develop and maintain an effective marketing and public relations strategy to promote fundraising opportunities.

Tell us a bit about the institution / company / organisation you work for

The Pasqual Maragall Foundation (PMF) for research in Alzheimer’s disease (AD) was established in April 2008, as the result of the public engagement of Pasqual Maragall, former mayor of Barcelona and president of the Government of Catalonia, when he announced he had been diagnosed with the disease. The PMF is affiliated to the Pompeu Fabra University in Barcelona (UPF) and develops its research in a joint center venture with UPF, the Barcelonaβeta Brain Research Center (BBRC).

BBRC addresses the challenges AD poses from a scientific point of view, with the decisive commitment to provide solutions and improve the welfare of persons affected by the disease. Its activity is directed at obtaining new scientific knowledge with the objectives of reducing the number of patients, delaying disease progression and providing solutions that improve the quality of life of both patients and their caregivers.

We also campaign to improve public understanding of AD and the devastating impact it can have, and make sure it is taken seriously and acted on by our governments.

Finally, the Foundation through its research centre, BBRC, is conducting the ALFA project for the prospective follow-up of a cohort of cognitively normal participants, many of them first-degree descendent of AD patients, with the aim of increasing our knowledge of the pathophysiology and pathogenic factors emerging at early preclinical AD stages. Within this project, the ALFA parent cohort is composed of 2743 cognitively healthy participants representing the whole spectrum of risk of developing AD that will leverage with different projects. One of these, the longitudinal ALFA+ cohort study will serve, through deep phenotyping, to untangle the natural history of the disease and to model its earliest stages to develop successful trials. Our most ambitious aim is to follow ALFA study participants throughout their lives.

BBRC is working for a future without AD: nowhere is it written that it is invincible.

What are your expectations from the EPAD project?

It is becoming increasingly more evident that many of the changes in the brain that lead to AD dementia start decades before symptoms appear. We therefore need to know how to identify these changes in middle-aged persons and also work out how we can intervene to stop them from progressing. We may be able to stop progression through specific pharmacological and non-pharmacological interventions.

My expectations are,

  1. To have an extensive pan-European cohort of persons at risk of developing Alzheimer’s dementia that will provide an extraordinary opportunity to better understand human biology behavior and compile enough information about risk factors to develop AD. Hopefully, this will allow us to,
  1. Find a treatment capable of preventing or delaying the evolution of the disease and the appearance of AD dementia.
  1. Finally, BBRC involvement in the EPAD project together with leading experts in the AD prevention research field, will enable collaborations between us and other groups similarly determined to fight against AD.
Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Edinburgh Dementia Prevention Summer School 2022
2022-06-30
EPAD at AAIC22!
2022-06-30
ADDI NeuroToolKit Data Hackathon
2022-05-17
The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
2022-05-09
First national follow-on study to EPAD LCS launches
2022-04-07
The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
2022-03-10
Latest News
  • Edinburgh Dementia Prevention Summer School 2022
    2022-06-30
  • EPAD at AAIC22!
    2022-06-30
  • ADDI NeuroToolKit Data Hackathon
    2022-05-17
  • The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
    2022-05-09
  • First national follow-on study to EPAD LCS launches
    2022-04-07
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

The @AlzData #NeuroToolKit Data Hackathon has started! 45 teams are uing the NTKApp, @IMI_EPAD datasets, and statistical analysis tools available on the #ADWorkbench to investigate the potential clinical utility of different biomarkers in #Alzheimer’s disease. twitter.com/AlzData/status…

reply retweet favorite
10:34 am · 2022-07-04
Twitter
EPAD
EPAD
@IMI_EPAD

The @CenDemPrevent Summer School, a 4-day interactive course on #brainhealth, is designed for clinicians, researchers and students. Space is limited, sign up quickly! 🗓️26-29 September 📍Edinburgh For more info, including programme⤵️ ep-ad.org/edinburgh-deme… pic.twitter.com/FSypbvWK4L

reply retweet favorite
12:38 pm · 2022-06-30
Twitter
EPAD
EPAD
@IMI_EPAD

There’s still time to join the @AlzData #NeuroToolKit #Data Hackathon! Registration closes on 24 June! Participants will work with @IMI_EPAD datasets and utilise the tools on the #ADWorkbench. Interested in participating? ➡️alzheimersdata.org/hackathon twitter.com/IMI_EPAD/statu…

reply retweet favorite
7:21 am · 2022-06-22
Twitter
EPAD
EPAD
@IMI_EPAD

Today, colleagues from @AlzData visited @CenDemPrevent to meet with those involved in various programmes including @IMI_EPAD @AD_PREVENT. Many relevant discussions and great catch-up! #BrainHealth #datasharing #collaboration @craig_ritchie68 @samdansobe @GregorySarah @CindyBirck pic.twitter.com/Mr3trKeuoz

reply retweet favorite
2:43 pm · 2022-06-15
Twitter
EPAD
EPAD
@IMI_EPAD

Have a look on the new @AlzheimerEurope #DementiaInEurope magazine featuring an article on @IMI_EPAD and its collaboration with @AlzData to make our data findable, accessible and reusable. @craig_ritchie68 ⤵️ alzheimer-europe.org/resource… twitter.com/AlzheimerEurop… pic.twitter.com/vLuW3HMLUh

reply retweet favorite
1:09 pm · 2022-06-14
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT